Welcome to our dedicated page for Check Cap SEC filings (Ticker: CHEK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Check-Cap’s ingestible imaging capsule might be straightforward for patients, but the regulatory story behind it spans hundreds of pages of foreign-issuer forms. Navigating clinical trial updates, cash runway disclosures and dilution risks hidden in shelf registrations can feel harder than swallowing the device itself. That’s why investors searching for Check-Cap insider trading Form 4 transactions or the latest Check-Cap quarterly earnings report 10-Q filing land here first.
Stock Titan’s AI reads every 6-K, 20-F, S-1, and 8-K within seconds, then delivers Check-Cap SEC filings explained simply. Need a quick Check-Cap earnings report filing analysis? Our models highlight R&D spend and trial milestones in plain language. Want real-time alerts? We stream Check-Cap Form 4 insider transactions real-time so you spot management’s moves the moment EDGAR publishes them.
The platform connects each filing type to the questions professionals actually ask:
- Cash & Dilution – shelf registration statements decoded so you know when new shares could hit the market.
- Clinical Progress – 6-K trial data tagged for easy trend analysis.
- Governance – the Check-Cap proxy statement executive compensation section is summarized, helping you benchmark incentives.
- Event Tracking – Check-Cap 8-K material events explained in minutes.
- Long-term View – the Check-Cap annual report 10-K simplified (20-F equivalent) pinpoints pivotal risk factors.
Whether you’re understanding Check-Cap SEC documents with AI or verifying Check-Cap executive stock transactions Form 4 before a capital raise, Stock Titan delivers every disclosure, every detail, and every insight—without the technical overload.
Check-Cap (CHEK) furnished a Form 6-K highlighting MBody AI’s enterprise traction and an upcoming merger vote on November 14. The filing describes MBody AI’s hardware-agnostic Orchestrator platform as the integration layer for robots and intelligent devices across factories, hotels, hospitals, and data centers. Reported outcomes from organizations using the platform include up to 40 percent labor reduction and 80 percent uptime improvement.
MBody AI notes multi-year, multi-million-dollar enterprise contracts, Fortune 500 and blue-chip deployments, and growing investor interest from major funds, family offices, and strategics totaling into the hundreds of millions of dollars. Company leaders frame the merger as positioning CHEK shareholders within embodied AI, supported by forward-looking statements that caution that actual results may differ due to market conditions, regulatory approvals, and integration risks.
Check-Cap Ltd. (CHEK) rescheduled its Annual General Meeting to November 14, 2025 at 10:00 a.m. ET at Paul Hastings LLP in Washington, DC. Shareholders of record as of September 16, 2025 may vote. The proxy materials previously furnished are incorporated by reference, with an updated Reverse Split Proposal range of 1-for-2 to 1-for-100. The number of authorized ordinary shares will remain 18,000,000, and the nominal value will remain NIS 48.0 per share even if the reverse split is approved.
The company also provided an update on its proposed merger with MBody AI. Under the September 12, 2025 Merger Agreement, a Check-Cap subsidiary will merge into MBody AI, which will survive as a wholly owned subsidiary of Check-Cap. The Board affirmed that the originally disclosed exchange ratio is being preserved. Subject to satisfaction or waiver of closing conditions and shareholder approval, the parties expect to consummate the merger in the weeks following approval.
Check-Cap (CHEK) furnished a business update on its pending merger with MBody AI and recent market activity. The company reported exceptional capital-markets engagement following the merger announcement, noting its shares increased by more than 300% and trading volumes reached the hundreds of millions of dollars in the days after the news.
The Board is evaluating potential financing opportunities to support the combined company’s growth strategy. No securities are being offered by this Form 6-K; any future financing would be conducted in compliance with applicable laws and regulations.
To allow additional time to assess financing options and amid elevated investor engagement, Check-Cap will reschedule its Annual General Meeting of Shareholders (originally set for October 17, 2025) and expects to announce a new date and record date in a subsequent Form 6-K.
FAQ
What is the current stock price of Check Cap (CHEK)?
What is the market cap of Check Cap (CHEK)?
